![Mark R.L. Krul](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark R.L. Krul
Fondateur chez
Aglaia Management BV
Profil
Dr. Krul has a background in molecular biology and immunology and over 12 years experience in anticancer drug development.
Before founding AGLAIA BioMedical Ventures he was Program Director of the NDDO Research Foundation.
He held several positions at NDDO Oncology BV, formerly the EORTC New Drug Development Office, with respect to oncology drug development strategies from 1997-2002 and was secretary of the Dutch Society of Gene Therapy.
From 1993 till 1997 Dr. Krul has been Research Manager of the European Cancer Center.
He has headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993.
In this period he organized a European concerted action “Immunology of human papillomaviruses and vaccine development”, also being the topic of his PhD thesis, which he defended at the University of Utrecht in 1996.
Postes actifs de Mark R.L. Krul
| Sociétés | Poste | Début |
|---|---|---|
Aglaia Management BV
 Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Fondateur | 15/04/2010 |
ORCA Therapeutics BV
 ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology Designs and develops virotherapy drugs | Directeur/Membre du Conseil | 03/07/2009 |
SomantiX BV
 SomantiX BV Miscellaneous Commercial ServicesCommercial Services Develops imaging and therapy of cancer through targeting of tumor blood vessels | Directeur Général | 09/06/2011 |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Develops, manufactures small bio molecule therapies for solid tumors | Directeur Général | - |
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Develops and manufactures nanomedicines for therapeutic drug optimization | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark R.L. Krul
| Sociétés | Poste | Fin |
|---|---|---|
NDDO Oncology BV
 NDDO Oncology BV Miscellaneous Commercial ServicesCommercial Services Provides product development support to pharmaceutical and biotechnology companies | Corporate Officer/Principal | - |
The European CanCer Organisation | Corporate Officer/Principal | - |
Rijksinstituut Voor Volksgezondheid En Milieu | Corporate Officer/Principal | 02/01/1993 |
Macrophage Pharma Ltd.
 Macrophage Pharma Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Directeur/Membre du Conseil | - |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Mark R.L. Krul
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
13
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
University of Utrecht
 University of Utrecht Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NDDO Oncology BV
NDDO Oncology BV Miscellaneous Commercial ServicesCommercial Services Provides product development support to pharmaceutical and biotechnology companies | Commercial Services |
Aglaia Management BV
Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Finance |
ISA Pharmaceuticals BV
 ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Develops novel therapeutic vaccines for cancer and infectious diseases | Health Technology |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology Designs and develops virotherapy drugs | Health Technology |
Merus NV
 Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
The European CanCer Organisation | |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology Engages in the development of novel breakthrough therapies in chronic disorders | Health Technology |
Netherlands Society of Gene Therapy | |
SomantiX BV
SomantiX BV Miscellaneous Commercial ServicesCommercial Services Develops imaging and therapy of cancer through targeting of tumor blood vessels | Commercial Services |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Develops and manufactures nanomedicines for therapeutic drug optimization | Health Technology |
Rijksinstituut Voor Volksgezondheid En Milieu | |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Health Technology |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Develops, manufactures small bio molecule therapies for solid tumors | Health Technology |
Modra Pharmaceuticals BV
 Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Designs and develops oral formulations of commonly used anti-cancer drugs | Health Technology |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
